玻璃体切除术后抗VEGF药物眼内药物代谢动力学研究进展

Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized eyes

新生血管性眼底病是一类发病率较高、能引起视力损害的眼病,目前主要治疗方法是玻璃体腔内注射抗血管内皮生长因子(VEGF)药物。临床上存在部分患者行玻璃体切除术或者其他眼科手术后,仍须抗VEGF药物治疗的情况。现有的研究表明,由于不同的手术方式及术后玻璃体腔内填充不同介质等影响因素,抗VEGF药物在玻璃体切除术后眼内药物代谢动力学与未行手术眼可能有所不同,因此应考虑是否需要根据其变化而改变治疗策略。本文对影响抗VEGF药物的药物代谢动力学因素,及其在玻璃体切除术后眼内的药物代谢动力学变化进行综述。

Neovascular retinal diseases pose a significant burden,often resulting in visual impairment.Intravitreal injection of anti-vascular endothelial growth factor(VEGF)drugs serves as the primary therapeutic approach.Nonetheless,certain patients necessitate continued anti-VEGF treatment post-vitrectomy or other ocular surgeries.Emerging evidence suggests that variations in surgical techniques and postoperative vitreous cavity management may induce distinct intraocular pharmacokinetics(PK)of anti-VEGF agents following vitrectomy,prompting potential adjustments in therapeutic strategies.This review offers a thorough examination of the pharmacokinetic determinants impacting anti-VEGF drugs and their intraocular dynamics post-vitrectomy.